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A B S T R A C T
A thermoresistive transdermal drug delivery patch based on a n-alkane wax phase change film is described. A
composite structure comprising a screen printed silver chloride heater sandwiched with a wax film loaded with
diclofenac was developed and the release characteristics upon heating were investigated. The drug is shown to
be immobile within the solid film (off state) but is readily delivered upon heating beyond the transition tem-
perature (37 °C). Drug delivery is maintained while the heater is active and terminates upon cooling. The system
has been shown to be capable of repetitive on-off cycling with control effected through a Bluetooth connection to
a smart phone app with dynamic feedback control/thermoregulation of the patch.
1. Introduction
Transdermal patches have long held promise as a route through
which therapeutic agents could be easily and painlessly delivered and
self-administered on demand [1–3]. Given the capability of avoiding
many of the issues associated with oral formulations and subcutaneous
injections, it is little surprise that interest in these systems has grown
considerably in recent years [4–8]. Transdermal delivery avoids many
of the harmful side effects associated with oral ingestion and gastro-
intestinal irritation and as first pass hepatic degradation is bypassed,
lower dosage of drugs is possible. The success of the delivery strategy is
evidenced in part by the availability of numerous commercial products
ranging from over the counter (OTC) nicotine [9,10] patches through to
prescription medicines such as estradiol [11], fentanyl [12,13], rivas-
tigmine [14], rotigotine [15] and diclofenac [16,17] covering hormone
replacement therapy, chronic pain, dementia, Parkinson’s disease and
acute pain respectively. The commercialisation of transdermal drug
patches has been progressing since 1979 and, while the nature of the
therapeutic agent and entrapment matrices can vary widely, the un-
derlying mechanism has remained relatively unchanged. In the vast
majority of cases, drug delivery is achieved by passive diffusion from
the patch reservoir across the stratum corneum through to the micro-
circulation [1,5–8]. As such, the rate of transfer is dependent on the
formulation of the drug patch and, once initiated, there is little means
of manipulating the dosing regime beyond the physical removal of the
patch. The evolution of transdermal patches towards smarter, stimuli
reactive, release dynamics has however gathered pace in recent years
with mechanical actuation, electrical activation, light initiation and
bioresponsive systems coming to the fore. These approaches have been
comprehensively reviewed elsewhere [4–8] but, of the four classes
mentioned, the electrical systems are perhaps the more readily adap-
table for use in miniaturised closed loop dosing regimes. In this in-
vestigation, electrical control over the thermal properties of a phase
change material is exploited as a means of controlling the dose yield
and dose frequency of diclofenac.
Phase change materials (PCM) have been used in a wide variety of
applications and typically transition from one phase to another upon
the application of an appropriate stimulus. In this particular case, the
PCM is based on a blend of alkanes which, at room temperature, will be
solid but, upon heating rapidly transform to the liquid state [18–21].
Such materials are extensively used in large scale energy conversion
applications as latent heat energy storage (LHES) systems [18,19] but
have also found application as actuators within microfluidic and mi-
croelectromechanical systems [20,21]. In such cases, the principal form
of actuation is through the volume change associated with the transi-
tion from solid to liquid. The application of alkane based PCMs for
transdermal drug delivery has yet to be explored and, in this in-
vestigation, the key mechanism is not volume change but rather the
change in viscosity of the medium.
The delivery methodology is based on the preparation of a thin film
of wax within which a model drug has been homogeneously distributed.
At room temperature, the drug loaded wax will be solid and the en-
trapped drug is rendered essentially immobile. Upon heating the ma-
terial, the wax becomes molten and the drug becomes free to move. The
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design approach adopted here involved combining a thin film of the
wax-drug composite with a screen printed heater element which could
be controlled via Bluetooth by an app from a smart phone as indicated
in Fig. 1A. The wax-drug composite is rinsed thoroughly with deionised
water before assembly. This has the effect of removing loosely bound
drug from the interface of the drug reservoir and thus, were the patch to
be applied to the skin, the solid nature of the composite would prevent
the transfer of any drug. Once the patch receives an appropriate signal
from the smartphone app – the heater is initiated and the temperature
increases to 45 °C. The wax will begin to transition from solid to liquid
and, in doing so, the entrapped drug will become mobile. At this point,
diffusion of the drug to the interface will occur (Fig. 1B) and will be free
to diffuse across the skin – much in the same way as a commercial OTC
patch. The critical advance in this work is that the drug will continue to
transfer as long as the wax is molten. A second (termination) signal sent
by the smart phone switches off the heater and the material will re-
solidify and the drug transfer will cease. Any drug remaining at the
interface would be expected to transfer up to the point of phase tran-
sition whereupon there will be no drug in contact with the skin. A
second dose could be applied to the patient through recommencing the
heating process and thus the proposed strategy offers and ability to
regulate repetitive dosing regimes and, in marked contrast to passive
patches, enact complex delivery profiles for transdermal administra-
tion.
In principle, as the heating element is based on a screen printed
silver-silver chloride ink, the core system (with the exception of the
Bluetooth receiver) would be disposable and thereby relatively in-
expensive to deploy. The design rationale behind the system is pre-
sented and the ability of the prototype patch to deliver diclofenac was
investigated.
2. Experimental details
2.1. Materials
Toluidine Blue O, paraffin wax pellets (76242), and diclofenac so-
dium were obtained from Sigma-Aldrich Company Ltd (Dorset,
England). A 50:50 Ag/AgCl paste (C2000215P4) with a solids content
of 81.14–83.14 % (at 130 °C) was supplied by Gwent Electronic
Materials Ltd. (Pontypool, UK). All chemicals purchased were of ana-
lytical grade and used without any further purification.
2.2. Microheater fabrication
A spiral-shaped microheater was designed using the DraftSight 2D
CAD package (Dassault Systèmes), with a track width of 1mm and ef-
fective heating area of 14 x 14mm. A screen manufactured by ASM
Assembly Systems (Dorset, England) was used in conjunction with a
DEK 240 manual screen printer to print the microheaters onto acetate
sheets using Ag/AgCl paste. The printed microheaters were then heated
in an oven at 120 °C for 600 s to ensure full solvent evaporation.
Scanning electron micrographs detailing the surface morphology of the
heater are shown in Fig. 2. Fig. 3.
2.3. Feedback loop
In order to maintain near constant temperature, a feedback loop was
designed in C++ and implemented using an Arduino Nano
ATmega328 P microcontroller board and Melexis MLX90614 non-con-
tact infrared thermometer. The microcontroller board was powered
using a microUSB cable in conjunction with a 5 V USB mains power
Fig. 1. Schematic of the PCM-heater patch operation. (A) before activation the
drug is immobile and not in contact with the skin. (B) Upon receiving an ap-
propriate Bluetooth signal – the heat is initiated, phase change occurs and the
drug is mobilised and able to transfer across the skin interface. (C) Once the
heating cycle is terminated, phase change occurs as the system cools and the
drug is once more rendered immobile.
Fig. 2. Scanning electron micrographs of the printed heater highlighting the
granular nature of the silver-silver chloride deposit.
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adapter, whilst the heater derived power from an external bench top
power supply, operated in continuous current mode. The desired tem-
perature was selected by adjustment of a potentiometer, with target and
current temperatures, as well as time elapsed displayed on a 128×64
OLED display module. A single channel 5 V relay was used to modulate
current flowing from the external power supply to the microheater,
with switching handled by the aforementioned microcontroller board.
Upon actuation of a heating cycle, the microcontroller board begins to
read values from the non-contact infrared thermometer. By comparing
the actual temperature readings to the target temperature set, the relay
is switched on or off so as to continue or discontinue heating, thus
enabling the pre-defined target temperature to be maintained. A suffi-
cient sampling rate was implemented to prevent deviation of more than
0.25 °C from the target set.
2.4. Bluetooth actuation
To engage a pre-programmed heating cycle, an Android application
was designed. The Arduino Nano ATmega328 P microcontroller board
was coupled with a HC-06 module, featuring a Cambridge Silicon Radio
BC417 2.4 GHz Bluetooth radio chip, enabling wireless communication
between the Android device and heating system. Following connection
to the on-board Bluetooth module, the user is presented with a number
of drug delivery profiles, allowing frequency and dosage to be adjusted
within a pre-defined limit. Visual confirmation of the delivery profile is
provided on the display module following selection.
2.5. Fabrication of the drug patch
The phase change material is based on a blend of hydrocarbons
traditionally used in commercial cosmetic applications and, at room
temperature, is present in the form of a wax. At temperatures ap-
proaching 45 °C, the wax transitions from solid to liquid. Diclofenac
was used as the model drug given its analgesic properties and the fact
that there are commercial diclofenac transdermal patches already
available [16,17]. It is also extensively used as a model in the devel-
opment of transdermal patch systems – those relying on purely passive
transfer [22–24] and those exploiting physical enhancement such as
heat or iontophoresis [25]. The sodium salt of diclofenac was mixed
with the molten wax and stirred until homogenously distributed. An
aliquot of the molten wax (600 μ L) was pipetted in a circular holder (⌀
18 x 2mm) and allowed to cool resulting in a thin solid film. The wax
disc was then washed with copious amounts of deionised water. The
hydrophobic nature of the wax disc prevents penetration of the water
into the core and thus only diclofenac present at the immediate inter-
face is removed. The screen printed heater was placed with the un-
printed acetate side in contact with the wax film. Thus, the application
of an appropriate voltage led to the generation of heat directly on the
acetate sheet but without the drug being in contact with the electrical
circuit.
2.6. Drug release studies
A Franz cell chamber was employed for the drug release studies and
the typical assembly is highlighted in Fig. 4. The drug loaded wax patch
was placed directly in contact with the receiving solution (deionised
water) and the heater laminate placed on top of the patch. The transfer
of the drug into the receiving chamber solution was determined
through extracting samples from the receiving arm and using UV–vis
spectroscopy to identify changes after each heat-cool cycle. The re-
ceiving solution was maintained at 22 °C.
3. Results and discussion
Toluidine Blue-O (TBO) was initially chosen as a model drug
through which to assess the release characteristics of the patch. The dye
provides simple but sensitive visual confirmation with the prime
chromophore peak process observed at 589 nm (ε=7.75×104 L
mol−1 cm−1). The heated patch system was mounted on a conventional
Franz cell without any separation membrane and thus the wax was in
direct contact with the aqueous layer in the receiving chamber. The
hydrophobicity of the wax prevented dissolution into the latter and,
providing the interface was rigorously washed prior to placement, no
transfer of TBO to the solution was observed. This was confirmed
through exposing the wax-TBO composite interface to the aqueous layer
and the receiving solution sampled at regular intervals over a period of
2 h. There was no change in UV–vis spectra over the analysis period
indicating that no leaching of the dye had occurred.
It was anticipated that activation of the heating element in contact
with the wax patch would raise the temperature of the wax beyond its
transition temperature (37 °C) resulting in a solid to liquid transition.
Once molten, it can be envisaged that the entrapped drug will be cap-
able of movement as a consequence of diffusion within the liquid wax.
This process should lead to an increase in the drug concentration at the
interface between the receiving solution and the wax and hence the
Fig. 3. Influence of applied voltage on the temperature recorded at the screen
printed heater element. (N= 3). Temperature measured with an infra-red
probe directed at the acetate substrate (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article).
Fig. 4. The patch system was mounted on a conventional Franz cell which
enabled sampling of the receiving volume for spectroscopic analysis.
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delivery of the drug to the former. One of the key challenges therefore
relates to the control of the heating component which will influence
delivery rate and drug yield. A critical underpinning factor is the
temperature of the patch as this will induce the mobilisation of the drug
and its transfer but must also be sufficiently low as to preclude dama-
ging the skin of the patient.
The temperature of the device can be controlled through a variety of
design factors but the aim here is not to provide an exhaustive ex-
ploration of these but rather to demonstrate proof of principle for the
proposed mechanism. As such, a single element design was chosen and
the heat regulated through controlling the current through the resistive
printed layer. A preliminary assessment of the heater/patch assembly
was performed using two current configurations: 100mA and 120mA.
These were selected on the basis that both demonstrated an ability to
reach the transition temperature of the wax relatively quickly – typi-
cally within 60 s of activation. A wax patch containing 5% wt. drug was
used as an initial model through which to investigate the thermal
performance of the prototype devices and determine the release char-
acteristics. The devices were assembled as per the schematic high-
lighted in Fig. 4 and the heating element activated for a period of 180 s.
A cooling period of 180 s was then employed before repeating the cycle.
The data obtained for the heater running at 100mA and 120mA over a
series of 5 consecutive cycles is detailed in Fig. 5.
The transition temperature is reached within 60 s of activation from
ambient temperatures (22 °C) and it can be seen that the temperature of
the wax continues to rise until the applied current is terminated. At this
point the wax begins to cool and re-solidify. The temperature decreases
but it can take in excess of 15min (for the 100mA system) to return to
ambient. The greater the applied current the greater the temperature
increase. In order to confirm that the drug is indeed mobilised during
these heating cycles, UV–vis spectra of the receiving solution were re-
corded immediately prior to the commencement of next heating cycle.
The spectra obtained for the 100mA system are detailed in Fig. 6A and
a quantitative comparison of the 100mA and 120mA systems is shown
in Fig. 6B.
There is a cumulative increase in the absorbance corresponding to
the released TBO with each cycle. It should be noted that when the
heating cycles are terminated (at least in the case of the 100mA system)
– no further increase in the absorbance band at 589 nm is observed
confirming that the phase change process is critical for mobilising the
drug and facilitating its transfer to the receiving solution.
There is a dramatic difference between the 100 and 120mA systems
and it could be tempting to suggest that the delivery yield could be
controlled through manipulation of the applied current. Examination of
the data presented in Fig. 5 highlights a number of issues with such an
assumption. Taking the first cycle as an example - in the case of the
120mA system, the temperature increases quicker and the cooling
period is longer such that the wax is in a molten state for longer than
the 100mA system and therefore there is more opportunity for the drug
to be transferred to the aqueous solution and hence the yield, as
highlighted in Fig. 6B, is greater. However, the temperature has risen
considerably beyond what would be considered a safe level for direct
application to human skin. In this particular scenario, the short dura-
tion of the cycles has meant that on subsequent cycles, the cooling
phase fails to return below the transition temperature and hence the
Fig. 5. Temperature change in response to current applied at 100mA and
120mA, demonstrating ramping effect in open-loop configuration.
Fig. 6. (A) UV–vis spectrum demonstrating increasing absorbance in the pre-
sence of TBO following each dosing cycle at 120mA. (B) The influence of ap-
plied current on the amount of drug released during a given release cycle.
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drug continues to be delivered. The 100mA system, in contrast, reaches
the maximum temperature limit of 45 °C in the first cycle within the
180 s heating duration. The cooling period is still too short however and
there is an emergence of a temperature ramp with each subsequent
cycle – rising to 48 °C by the end of cycle 5. In practical terms the
cooling period can be longer to allow the return to ambient but there is
a clear restriction in terms of the heating cycle and hence the amount
that can be delivered. Analysis of the UV–vis spectra reveals that the
average amount of drug delivered per cycle (at 100mA) is 3.13 μg ±
0.596 μg. Increasing the drug yield through increasing the duration
over which the heater is activated in this simple system would mean
that the temperature will also rise beyond the 45 °C limit.
The simple unregulated application of a constant current to the
heater is clearly untenable for the proposed application. It is clear that
while the use of phase change material can enable repetitive dosing
through the application of a heating cycle, additional protective mea-
sures would be required to ensure that the temperature does not exceed
the safety limit. A feedback circuit was constructed based on the in-
tegration of a Melexis non-contact IR sensor and associated control
circuit (detailed within the supporting information) and software. This
limits the current such that the temperature is fixed at 45 °C. A com-
parison between the unregulated and feedback systems for the 120mA
configuration over 5 cycles is shown in Fig. 7.
While the temperature of the unregulated system ramps sig-
nificantly with increasing cycles, the feedback system maintains a peak
temperature of 45 °C throughout as indicated in Fig. 7 and detailed in
Table 1. The temperature variation within a given cycle at the peak
temperature was found to be 0.05 (based on N=5), with 8 discrete
values recorded during the plateau of each cycle.
The introduction of the feedback system effectively removes the
option of controlling the rate of release through the manipulation of the
current but, crucially, it proffers an opportunity to facilitate drug re-
lease beyond 180 s and thereby enable increased boluses to be attained
without the risk of thermal damage to the skin.
The modified feedback system combined with Bluetooth control was
further evaluated using diclofenac as a target drug. Diclofenac is a
common analgesic that is already used in transdermal patch systems
and therefore serves as an ideal test to the system. The drug was in-
corporated into the wax through the same procedures as those used
with TBO and the resulting thin film washed and mounted in the Franz
cell along with the Bluetooth controlled heater circuit. The receiving
solution was sampled every 10min and the absorbance spectra ana-
lysed for the presence of diclofenac. The latter lacks any visible chro-
mophore and, as such, its release was detected through the increase in
absorbance at 279 nm. It must be noted that the paraffin wax is pre-
dominantly saturated hydrocarbon with no appreciable UV active
groups and thus presents no direct interference to the measurement.
Under conditions in which the heater was dormant, no release of the
diclofenac into the receiving chamber was observed. In contrast, the
activation of the heater (45 °C) results in the transport of the diclofenac
with the heat-cool cycles resulting in cumulative dosing. A quantitative
comparison highlighting the drug release under active and dormant
actions is detailed in Fig. 8.
A quantitative comparison of the drug released per 10min cycle is
detailed in Fig. 9 (based on 3 individual patches).
It was also necessary to assess the effect of the drug loading and
release on the thermal dynamics of the proposed patch to determine if
the presence of the drug unduly comprised the solid-liquid transition.
Three patches containing different loadings of diclofenac (1–10 %)
were assessed to determine how the increased loading would affect the
temperature response. The data for three samples is highlighted in
Fig. 10 and it can be seen that the response is relatively independent of
the drug loading.
4. Discussion
It has been shown that increasing the skin temperature from a
Fig. 7. Effects of repeated heating and cooling cycles, with and without feed-
back control implementation.
Table 1
Comparison of unregulated and feedback control on temperature of the wax
film.
Unregulated System Feedback Regulated System
Cycle Max T / °C Max T / °C N Mean T / °C Error +/−
1 50.93 45.41 8 45.24 0.066
2 56.05 45.39 8 45.14 0.069
3 58.71 45.47 8 45.18 0.070
4 60.27 45.49 8 45.23 0.059
5 61.29 45.53 8 45.31 0.086
Fig. 8. Comparison in release of diclofenac sodium (μM) over time when heated
to 45 °C and at room temperature (20 °C).
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baseline 32 °C by 9–13 °C leads to a 6–7 fold increase in local blood flow
[26,27] and results in structural changes within the stratum corneum
that affect the diffusion, partitioning and barrier properties of the skin.
Increasing the skin temperature between 35 and 42 °C is known to
disrupt the ceramides, fatty acids, cholesterol and its associated esters
that form the lipid bilayers [28–31]. At 37 °C the lipids covalently
bonded to the corneocytes are disrupted and there is a solid to fluid
transition [32–34] which results in increased conformational freedom
in the lipid bilayer. The latter is often cited as the reason for increased
drug partitioning [35] and therein facilitates increased skin absorption
of potential drugs but, it has to be noted, that the effect of heat on
transdermal drug delivery is further complicated by the widely varied
designs and formulations used in patches. The behaviour of chemically
distinct patch components, either individually or within a complex
formulation mixture combined within an equally complex and variable
skin structure are difficult to anticipate and a generic model is elusive.
It is however clear that variations in local of skin temperature can
therefore dramatically impact the clinical efficacy and/or safety of
transdermal and topical drug products. Wood et al. (2012) for example
demonstrated that increased partitioning of lidocaine base into the
epidermis and increased epidermal diffusion were observed at 45 °C as
compared with that at 32 °C with a 519% boost in diffusivity [31].
Although subjects have reported discomfort when in direct contact with
a heat source upon reaching 43 °C, with the potential for skin damage
occurring following a further increase of 1–2 °C, it has been estimated
that such damage is minimal and likely to be transient [36,37]. Otto
et al. (2014) report that temperatures of up to 45 °C are “physiologically
tolerable to the human skin” [38], with a number of heat-assisted drug
permeation studies such as that carried out by Akomeah et al. (2004)
limiting their temperature range to 45 °C so as to “minimise thermal
damage to the skin” [39]. It is important to note that the heat source
and infrared sensor within the Wax PCM patch are not in direct contact
with the skin, but rather on the outer side of the wax disc. Therefore, it
can be anticipated that the temperature at the wax-skin interface will be
somewhat lower than that of the wax-heater interface, minimising the
potential for skin damage. Should the melting point of the wax used in
the current investigation be deemed too high, posing risk to the patient,
an alternative blend of hydrocarbon waxes with a lower melting point
may be employed in its place. Skin temperature under normal condi-
tions will be dependent on a host of factors but typically resides around
33 °C and has been shown to rise to around 40 °C during exercise in a
hot environment [40–42], and it is obvious that fluctuations in local
heat could result in the variations in dosing which could be detrimental
to the patient.
Rather than being the passively susceptible to spikes in drug dosing,
one option is to actively control the temperature by raising the patch
beyond the ambient surrounding. The active use of heat as a method
through which to enhance percutaneous drug absorption has a long
history (Blank et al, 1967) but its practical application has failed to
acquire significant commercial support [43]. Synera™, a transdermal
patch for the delivery of lidocaine and tetracaine, is one of the few
successful entries and utilises an integral chemical heat pad (CHADD™)
based on the air oxidation of iron powder to raise the temperature to
around 40–41 °C [44,45]. It could similarly be expected that the ap-
plication of the Wax PCM patch investigated here would similarly
benefit from the increased temperature enhancing drug transfer
through the skin and the electronic regulation of the temperature
helping to eliminate the variations (and hence dosage spikes) that can
beset simpler systems.
The direct application of heat as a means of initiating the release of
drugs rather than simply controlling the rate of release has begun to
generate interest – particularly through advances in microdevice de-
velopment and responsive materials. Miniaturised electro-resistive
heaters [46–52] and photothermal systems [53,54] are two of the
current methodologies with the Wax PCM patch falling within the remit
of the former. Printed heater systems have been shown to be particu-
larly amenable to wearable applications through their inherent flex-
ibility and ability to conform to the variable surface morphologies of
the skin. As the resistance of a material is proportional to length and
cross-sectional area, the heating profile of the microheater can be
maintained whilst scaling the effective heating area, assuming both
factors are also scaled accordingly. These are typically employed
alongside thermo-responsive micro/nano particulate carriers which
undergo a structural change (swelling, shrinking, dissolution) upon
reaching a critical temperature and therein release the drug. These
devices typically employ discrete micro structures and it could be ar-
gued that the wax film offers a far simpler approach (compositionally
and procedurally) to the fabrication of the devices. The critical ad-
vantage however is the ability to initiate repetitive dosing cycles
through the repeated cooling (off) and heating (on) cycles.
5. Conclusions
Transdermal drug delivery offers a great number of advantages over
Fig. 9. Diclofenac Sodium release (μg) per 10min heating/cooling cycle.
Fig. 10. Effects of drug loading on temperature during heating and cooling
cycles.
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conventional oral and injection methods but the variability of the skin
interface, ambient conditions and local heat arising through activity are
factors that affect the delivery rate. Moreover, many of the patch sys-
tems invoke passive transfer upon application while there is an in-
creasing demand for devices that can provide a drug bolus upon acti-
vation of a specific trigger. There is considerable interest in the
development of thermal activation and the wax film matrix described
here adopts this methodology and provides a simple route through
which drug release can be initiated, maintained with controllable on-off
cycling over protracted periods.
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